Examiner Cite

No

Initial\*

Kind

Code1

If you wish to add additional U.S. Patent citation information please click the Add button.

WO

Issue Date

Remove

Add

Add Remove

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

PTO/SB/08+ (01-10)

	Filing
STATEMENT BY ADDITIONAL	First N
	Art Un
	Exami

Patent Number

Application Number		09682583
Filing Date		2001-09-21
First Named Inventor David		N. Brotherston
Art Unit		3691
Examiner Name	Akinto	ola, Olabode
Attorney Docket Number		P3S2002336US

Name of Patentee or Applicant

PTY LIMITED

of cited Document

U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite	No Publication Number	Kind Code <sup>1</sup>		Publication Date Name of Patentee or of cited Document			Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1						J		Add .	
If you wis	n to a	dd additional U.S. Pub				ENT DOCUM		d butto	Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	y K	ind	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS
	1	2033054	CA	A	1	1990-12-01	GEC-Marconi Limit	ed		
	2	05/27040	wo			1005 10 10	VISUAL TECHNOL	.OGY		

NON-PATENT LITERATURE DOCUMENTS

A1 1995-10-19

If you wish to add additional Foreign Patent Document citation information please click the Add button

U.S.PATENTS

95/27949

#### 

Examiner Initials*	Cite No					
	1					

If you wish to add additional non-patent literature document citation information please click the Add button Add

# EXAMINER SIGNATURE Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1.5ex Kind Codes of USPTO Patient Documents at year LISETO\_CODE or MRCP 901.64. <sup>2</sup> Exits office that issued the document, by the how-lefter code (WIPO Standard ST3), <sup>3</sup> For Japanese patient Concurrent, by mischool on the year of the Proprior many precedure he resident number of the patient concurrent, <sup>4</sup> Kind of documents by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. <sup>3</sup> Applicant is to place a check mark here if English language in translation in a standors.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09682583
Filing Date		2001-09-21
First Named Inventor	David	N. Brotherston
Art Unit		3691
Examiner Name	Akinto	ola, Olabode
Attorney Docket Number		P3S2002336US

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

Brian D Furror

# SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	form of the signature.			
	Signature	/Brian P. Furrer/	Date (YYYY-MM-DD)	2012-01-11

Registration Number

37627

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Comments of December 2.0 beat 1450, Alexandria, V.S. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213-1450.

Name/Print

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicide to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested process andior examine your submission related to a patient application or patient. If you do not furnish the requested required to the procession of the submission, which may result in fearning-time of proceedings or a banderiness of the separation of the submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552(am).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
  the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
  may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
  an application which became abandoned or in which the proceedings were terminated and which application is
  referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.